Nascent Biotech, Inc. (NBIO) Research

Nascent Biotech, Inc., a clinical-stage biopharmaceutical firm, is committed to creating monoclonal antibody-based treatments for various forms of cancer. A primary focus is Pritumumab, a therapeutic currently in development to address aggressive brain malignancies such as glioblastoma and malignant astrocytoma. This drug also targets numerous epithelial cancers, including those affecting the lung, breast, colon, brain, and pancreas. Additionally, the company is advancing MultiPharm, its proprietary technology platform, which holds promise for applications in cancer therapy, diabetes, autoimmune disorders, and transplantation. The company's headquarters are situated in Vero Beach, Florida.

Market snapshot

Symbol
NBIO
Price
$0.00
Day change
+66.67%
Market cap
$86.1K
P/E ratio
-0.04x
52-week range
0.0001-0.1345
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • BioSyntech, Inc. (BSYI)
  • ChitogenX Inc. (CHNXF)
  • Plant-Based Investment Corp. (CWWBF)
  • First Choice Healthcare Solutions, Inc. (FCHS)
  • Pazoo, Inc. (PZOO)
  • Actavia Life Sciences, Inc. (RASP)
  • RegeneRx Biopharmaceuticals, Inc. (RGRX)
  • Real Brands, Inc. (RLBD)

Recent insider activity

  • Karas Douglas John — J-Other (50000 shares) on 2024-06-30
  • HOLDEN LOWELL THOMAS — J-Other (96000 shares) on 2024-06-30
  • Carrick Sean — J-Other (192000 shares) on 2024-06-30
  • HOLDEN LOWELL THOMAS — J-Other (112500 shares) on 2024-03-31
  • Carrick Sean — J-Other (225000 shares) on 2024-03-31

Open Nascent Biotech, Inc. (NBIO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.